BUZZ-Structure Therapeutics down ahead of weight-loss drug data

Reuters12-08

BUZZ-Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> down ahead of weight-loss drug data

** Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket

** The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity

** The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound both of which dominate the market

** Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August

** As of last close, GPCR stock was up 27.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589337672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589337672","market":"us","top_or_hot":-1,"title":"BUZZ-Structure Therapeutics down ahead of weight-loss drug data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> down ahead of weight-loss drug data </title></head><body><p>** Shares of Structure Therapeutics <span>GPCR.O</span> falls 1.4% to $34.1 premarket </p><p>** The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity</p><p>** The current landscape for obesity treatments includes Danish drugmaker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s <span>NOVOb.CO</span> Wegovy and Eli Lilly's <span>LLY.N</span> Zepbound both of which dominate the market</p><p>** <a href=\"https://laohu8.com/S/VKTX\">Viking</a> Therapeutics' experimental weight-loss pill VK2735 <span>previously failed to</span> surpass Wall Street expectations in August </p><p>** As of last close, GPCR stock was up 27.4% YTD </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Structure Therapeutics down ahead of weight-loss drug data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Structure Therapeutics down ahead of weight-loss drug data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 19:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> down ahead of weight-loss drug data </title></head><body><p>** Shares of Structure Therapeutics <span>GPCR.O</span> falls 1.4% to $34.1 premarket </p><p>** The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity</p><p>** The current landscape for obesity treatments includes Danish drugmaker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s <span>NOVOb.CO</span> Wegovy and Eli Lilly's <span>LLY.N</span> Zepbound both of which dominate the market</p><p>** <a href=\"https://laohu8.com/S/VKTX\">Viking</a> Therapeutics' experimental weight-loss pill VK2735 <span>previously failed to</span> surpass Wall Street expectations in August </p><p>** As of last close, GPCR stock was up 27.4% YTD </p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0NY:1","article_id":"2589337672","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589337672","pubTimestamp":1765194673,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Structure Therapeutics downahead of weight-loss drug data** Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket ** The drug developer on December 8 is set to release data from a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","VKTX":"Viking Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4007":"制药"},"translate_title":"BUZZ-Structure Therapeutics在减肥药物数据公布前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9,"VKTX":0.9},"content_text":"BUZZ-Structure Therapeutics down ahead of weight-loss drug data ** Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket ** The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity** The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound both of which dominate the market** Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August ** As of last close, GPCR stock was up 27.4% YTD  (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589337672","isCrawlerRequest":true}